Furthermore, CD11b+ monocytes from mouse ascites activated ex vivo with a combination of TLR 4 and TLR 9 agonists moderately extended survival when provided prophylactically, and led to tumor rejection and long-term memory in the therapeutic setting, further underscoring the important role of TLR stimulation in effective ovarian cancer immunotherapies [55]. Here, ITGAM is linked to ovarian cancer.